130 related articles for article (PubMed ID: 3320577)
1. Combination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromes.
Ho AD; Martin H; Knauf W; Reichardt P; Trümper L; Hunstein W
Leuk Res; 1987; 11(11):1041-4. PubMed ID: 3320577
[TBL] [Abstract][Full Text] [Related]
2. Therapy of 'high risk' myelodysplastic syndromes with an association of low-dose Ara-C, retinoic acid and 1,25-dihydroxyvitamin D3.
De Rosa L; Montuoro A; De Laurenzi A
Biomed Pharmacother; 1992; 46(5-7):211-7. PubMed ID: 1467449
[TBL] [Abstract][Full Text] [Related]
3. Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG).
Hellström E; Robèrt KH; Samuelsson J; Lindemalm C; Grimfors G; Kimby E; Oberg G; Winqvist I; Billström R; Carneskog J
Eur J Haematol; 1990 Nov; 45(5):255-61. PubMed ID: 2261951
[TBL] [Abstract][Full Text] [Related]
4. [Effect of treatment with 13-cis-retinoic acid and ara-C on the hematopoietic stem cells of patients with myelodysplastic syndromes].
García Marco J; Miguel Sosa A; García Conde J; Miguel García A; Arbona C; Escrig V; Benet I; Navarro I; Ruiz A; Carbonell F
Sangre (Barc); 1994 Aug; 39(4):241-4. PubMed ID: 7985051
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
[TBL] [Abstract][Full Text] [Related]
6. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.
Venditti A; Tamburini A; Buccisano F; Scimò MT; Del Poeta G; Maurillo L; Cox MC; Abruzzese E; Tribalto M; Masi M; Amadori S
Ann Hematol; 2000 Mar; 79(3):138-42. PubMed ID: 10803936
[TBL] [Abstract][Full Text] [Related]
7. Differentiation therapy of myelodysplastic syndromes with retinoic acid.
Ohno R
Leuk Lymphoma; 1994 Aug; 14(5-6):401-9. PubMed ID: 7812199
[TBL] [Abstract][Full Text] [Related]
8. All trans retinoic acid with low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
Nair R; Nair CN; Advani SH
Leuk Lymphoma; 1998 Mar; 29(1-2):187-92. PubMed ID: 9638988
[TBL] [Abstract][Full Text] [Related]
9. [Low dose all-trans retinoic acid and androgen therapy for patients with myelodysplastic syndrome].
Guan M; Chen SC; Li RS; Ge CW; Zhu HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):774-8. PubMed ID: 15631659
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Weihrauch MR; Staib P; Seiberlich B; Hoffmann M; Diehl V; Tesch H
Leuk Lymphoma; 2004 Apr; 45(4):699-704. PubMed ID: 15160942
[TBL] [Abstract][Full Text] [Related]
11. High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
Hiçsönmez G; Tuncer AM; Sayli T; Güler E; Cetin M; Ozbek N; Mufti GJ
Hematol Pathol; 1995; 9(3-4):185-93. PubMed ID: 8655463
[TBL] [Abstract][Full Text] [Related]
12. Low-dose Ara-C in myelodysplastic syndromes and acute nonlymphoid leukemia. Experience with seven patients.
Bruzzese L; Abbadessa A; Ottaiano L; Arcidiacone G
Haematol Blood Transfus; 1987; 30():315-21. PubMed ID: 3623239
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor.
Hofmann WK; Ganser A; Seipelt G; Ottmann OG; Zander C; Geissler G; Hoffmann K; Höffken K; Fischer JT; Isele G; Hoelzer D
Ann Hematol; 1999 Mar; 78(3):125-30. PubMed ID: 10211754
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome.
Clark RE; Ismail SA; Jacobs A; Payne H; Smith SA
Br J Haematol; 1987 May; 66(1):77-83. PubMed ID: 3297129
[TBL] [Abstract][Full Text] [Related]
15. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
Guan M; Chen SC; Ge CW
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of myelodysplastic syndrome by combined traditional Chinese medicine and Western medicine therapy].
Wang XT; He HT
Zhongguo Zhong Xi Yi Jie He Za Zhi; 1993 Jul; 13(7):410-2, 388. PubMed ID: 8251723
[TBL] [Abstract][Full Text] [Related]
17. Differentiation induction in myelodysplasia and acute myeloid leukaemia: use of synergistic drug combinations.
Francis GE; Mufti GJ; Knowles SM; Berney JJ; Guimaraes JE; Secker-Walker LM; Hamblin TJ
Leuk Res; 1987; 11(11):971-7. PubMed ID: 3480401
[TBL] [Abstract][Full Text] [Related]
18. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study.
Aul C; Runde V; Gattermann N
Blood; 1993 Nov; 82(10):2967-74. PubMed ID: 8219188
[TBL] [Abstract][Full Text] [Related]
19. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study.
Miller KB; Kim K; Morrison FS; Winter JN; Bennett JM; Neiman RS; Head DR; Cassileth PA; O'Connell MJ
Ann Hematol; 1992 Oct; 65(4):162-8. PubMed ID: 1420504
[TBL] [Abstract][Full Text] [Related]
20. Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study.
Hofmann WK; Kell WJ; Fenaux P; Castaigne S; Ganser A; Chomienne C; Burnett R; Kowal C; Hoelzer D; Burnett AK
Leukemia; 2000 Sep; 14(9):1583-8. PubMed ID: 10995004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
